Emerging Targets in Non‑Small Cell Lung Cancer
Sotorasib is the first drug approved for the treatment of locally advanced or metastatic KRAS G12C‑mutant non‑small cell lung cancer.
The identification of molecular driver mutations in non‑small cell lung cancer (NSCLC) has changed the therapeutic landscape for this disease. Over the last 20 years, a growing number of driver mutations have been identified in addition to new targeted therapies that have resulted in significant improvement in survival for a subset of patients. There is ongoing research to identify additional molecular targets and therapeutic strategies to improve outcomes in a greater percentage of patients with lung cancer. This review aims to highlight new therapeutic strategies targeting known driver mutations and data regarding emerging molecular targets for the treatment of NSCLC.
Targeted therapies have significantly improved survival for patients with driver‑gene–positive NSCLC, yet most patients remain unresponsive or develop resistance. Identifying and validating new actionable mutations and effective inhibitors is therefore critical for expanding treatment options and improving outcomes.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT